Triptorelin

Generic Name: Triptorelin

Brand Names: Decapeptyl, Trelstar, Triptodur

Drug Type: Small Molecule

Chemical Formula: C_₆₄H_₈₂N_₁₈O_₁₃

CAS Number: 57773-63-4

Unique Ingredient Identifier: 9081Y98W2V

Background: Triptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. Serum testosterone concentrations may fall to levels typically observed in surgically castrated men.

Indication: Triptorelin is indicated for the palliative treatment of advanced prostate cancer.

Associated Conditions: Advanced Prostate Cancer

Associated Therapies: Controlled ovarian hyperstimulation therapy

Clinical Trials

Can GnRH Agonist Trigger Prevent Ovarian Hyperstimulation Syndrome?

Phase 4

Terminated

Conditions: Ovarian Hyperstimulation Syndrome

Interventions: Drug: Triptorelin 0.2 mg

First Posted Date: 2012-10-26

Last Posted Date: 2015-08-04

Lead Sponsor: Elisha Hospital

Target Recruit Count: 6

Registration Number: NCT01714648

Locations: 🇮🇱
IVF Unit, Elisha Hospital, Haifa, Israel

Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: Triptorelin Pamoate 11.25mg

First Posted Date: 2012-10-26

Last Posted Date: 2019-12-09

Lead Sponsor: Ipsen

Target Recruit Count: 126

Registration Number: NCT01715129

GP Extended Action Triptorelin

Phase 4

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Decapeptyl® SR 22.5mg
Drug: Decapeptyl® SR 11.25mg; Prostap® 3 DCS 11.25mg; Zoladex® LA 10.8mg

First Posted Date: 2012-08-28

Last Posted Date: 2020-11-05

Lead Sponsor: Ipsen

Target Recruit Count: 27

Registration Number: NCT01673984

Locations: 🇬🇧
Danes Camp Surgery, Northampton, United Kingdom
🇬🇧
The Porch Surgery, Corsham, United Kingdom
🇬🇧
Waterloo Medical Centre, Blackpool, United Kingdom

and more 32 locations

Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: Triptorelin embonate 22.5 mg

First Posted Date: 2012-08-02

Last Posted Date: 2015-09-15

Lead Sponsor: Debiopharm International SA

Target Recruit Count: 120

Registration Number: NCT01656161

Locations: 🇿🇦
East Rand Urology Research Unit, Clinix Private Clinic, Johannesburg, Gautang, South Africa
🇿🇦
Paarl Medical Centre, Paarl, Cape Town, Western Cape, South Africa
🇿🇦
Department of Urology, Tygerberg Hospital, Tygerberg, Cape Town, South Africa

and more 7 locations

Final Oocyte Maturation Via Administration of GnRH Agonists Followed By Luteal Support With hCG

Phase 4

Completed

Conditions: Infertility

Interventions: Drug: TRIPTORELIN ACETATE, hCG

First Posted Date: 2012-07-11

Last Posted Date: 2017-08-29

Lead Sponsor: HaEmek Medical Center, Israel

Target Recruit Count: 93

Registration Number: NCT01638026

Locations: 🇮🇱
Hemek medical centre, Afula, Israel

Trial Comparing hCG Triggering Versus hCG Associated With GnRH Agonist

Phase 4

Completed

Conditions: Infertility

Interventions: Drug: Decapeptyl Daily
Drug: pregnyl

First Posted Date: 2012-05-30

Last Posted Date: 2015-02-19

Lead Sponsor: AZ Jan Palfijn Gent

Target Recruit Count: 120

Registration Number: NCT01607203

Locations: 🇧🇪
A Z Jan Palfijn, Gent, Oost-vlaanderen, Belgium

The Effect of Pre-treatment With GnRH Analogues Prior in Vitro Fertilization in Patients With Endometriosis

Phase 4

Completed

Conditions: Endometriosis
Infertility

Interventions: Drug: Triptorelin acetate

First Posted Date: 2012-04-20

Last Posted Date: 2015-10-22

Lead Sponsor: Instituto de Investigacion Sanitaria La Fe

Target Recruit Count: 200

Registration Number: NCT01581359

Locations: 🇪🇸
Human Reproduction Unit of the La Fe University and Politechnic Hospital, Valencia, Spain

Endometrial Receptivity After GnRH Agonist Triggering

Phase 4

Completed

Conditions: Ovarian Hyperstimulation Syndrome

Interventions: Drug: triptorelin, hCG
Drug: triptorelin, recombinant LH
Drug: Triptorelin, estradiol valerate, micronized vaginal progesterone
Drug: hCG
Drug: triptorelin

First Posted Date: 2011-12-29

Last Posted Date: 2016-10-26

Lead Sponsor: IVI Madrid

Target Recruit Count: 35

Registration Number: NCT01500863

Locations: 🇪🇸
Instituto Valenciano de Infertilidad, Madrid, Spain

Ovarian Stimulation Using Recombinant Follicle-stimulating Hormone (FSH) and Gonadotrophin Releasing Hormone (GnRH) Agonist in Alternate Days

Not Applicable

Completed

Conditions: Infertility

Interventions: Drug: Triptorelin
Drug: Cetrorelix

First Posted Date: 2011-11-09

Last Posted Date: 2012-07-13

Lead Sponsor: Fertility - Assisted Fertilization Center

Target Recruit Count: 96

Registration Number: NCT01468441

Locations: 🇧🇷
Fertility - Assisted Fertilization Center, Sao Paulo, Brazil

Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty

Phase 3

Completed

Conditions: Central Precocious Puberty

Interventions: Drug: Triptorelin

First Posted Date: 2011-11-09

Last Posted Date: 2017-07-28

Lead Sponsor: Debiopharm International SA

Target Recruit Count: 44

Registration Number: NCT01467882

Locations: 🇺🇸
Swedish Pediatric Specialist, Seattle, Washington, United States
🇨🇱
IDIMI, Santiago, Chile
🇲🇽
Hospital Universitario de Monterrey, Monterrey, Mexico

and more 9 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy